These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 27625344)

  • 1. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
    Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
    Roth EM; Moriarty PM; Bergeron J; Langslet G; Manvelian G; Zhao J; Baccara-Dinet MT; Rader DJ;
    Atherosclerosis; 2016 Nov; 254():254-262. PubMed ID: 27639753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
    Roth EM; Taskinen MR; Ginsberg HN; Kastelein JJ; Colhoun HM; Robinson JG; Merlet L; Pordy R; Baccara-Dinet MT
    Int J Cardiol; 2014 Sep; 176(1):55-61. PubMed ID: 25037695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
    Roth EM; Kastelein JJP; Cannon CP; Farnier M; McKenney JM; DiCioccio AT; Brunet A; Manvelian G; Sasiela WJ; Baccara-Dinet MT; Zhao J; Robinson JG
    J Clin Lipidol; 2020; 14(5):707-719. PubMed ID: 32928709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
    Colhoun HM; Robinson JG; Farnier M; Cariou B; Blom D; Kereiakes DJ; Lorenzato C; Pordy R; Chaudhari U
    BMC Cardiovasc Disord; 2014 Sep; 14():121. PubMed ID: 25240705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
    Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk Chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese sub-population analysis].
    Han YL; Ma YY; Su GH; Li Y; Li Y; Liu DF; Song R; Li JY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):593-599. PubMed ID: 32842270
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
    Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
    Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
    Santos RD; Wiegman A; Caprio S; Cariou B; Averna M; Poulouin Y; Scemama M; Manvelian G; Garon G; Daniels S
    JAMA Pediatr; 2024 Mar; 178(3):283-293. PubMed ID: 38315470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.